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Aims: Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor deficits and 
degeneration of dopaminergic neurons. Caused by a number of genetic and environmental factors, 
mitochondrial dysfunction and oxidative stress play a role in neurodegeneration in PD. By selectively knocking 
out mitochondrial transcription factor A (TFAM) in dopaminergic neurons, the transgenic MitoPark mice 
recapitulate many signature features of the disease, including progressive motor deficits, neuronal loss, and 
protein inclusions. In the present study, we evaluated the neuroprotective efficacy of a novel mitochondrially 
targeted antioxidant, Mito-apocynin, in MitoPark mice and cell culture models of neuroinflammation and 
mitochondrial dysfunction. 
Results: Oral administration of Mito-apocynin (10 mg/kg, thrice a week) showed excellent central nervous 
system bioavailability and significantly improved locomotor activity and coordination in MitoPark mice. 
Importantly, Mito-apocynin also partially attenuated severe nigrostriatal degeneration in MitoPark mice. 
Mechanistic studies revealed that Mito-apo improves mitochondrial function and inhibits NOX2 activation, 
oxidative damage, and neuroinflammation. 
Innovation: The properties of Mito-apocynin identified in the MitoPark transgenic mouse model strongly 
support potential clinical applications for Mito-apocynin as a viable neuroprotective and anti-
neuroinflammatory drug for treating PD when compared to conventional therapeutic approaches. 
Conclusion: Collectively, our data demonstrate, for the first time, that a novel orally active apocynin derivative 
improves behavioral, inflammatory, and neurodegenerative processes in a severe progressive dopaminergic 
neurodegenerative model of PD. Antioxid. Redox Signal. 27, 1048–1066. 
Keywords 
mitochondria, Parkinson’s disease, Mito-apocynin, apocynin, neuroprotection 
Introduction 
Parkinson's disease (pd) is a debilitating neurodegenerative disorder, affecting millions of people worldwide and 
is triggered by a complex interplay of genetic and environmental factors. PD neuropathology is characterized by 
a loss of dopaminergic neurons in the substantia nigra (SN), loss of dopamine (DA) in the striatum, and 
accumulation of abnormal α-synuclein protein, a major constituent of Lewy bodies and Lewy neurites (63). 
Motor symptoms such as bradykinesia, tremor, rigidity, and postural instability are still used to clinically 
diagnose PD. Although it is known that neuronal loss leads to DA deficiency and motor dysfunction, less is 
understood regarding the mechanisms underlying the loss of SN neurons (55). Neuroinflammation, oxidative 
stress, and mitochondrial dysfunction have all been implicated in PD pathogenesis (65, 68). Although 
mitochondrial dysfunction is well established as an overriding pathophysiological indication of PD, no effective 
treatment options are available to improve the efficiency of mitochondrial function in PD. 
Innovation 
Advances in drug discovery for neurodegenerative diseases have been hampered by the lack of models 
that recapitulate the chronic, progressive neurodegeneration characteristic of Parkinson's disease (PD). 
However, a recently developed genetic model of mitochondrial dysfunction, known as MitoPark mice, 
mirrors many key features of PD. Recently, we developed a new class of pharmacological agents to 
effectively dampen the major pathophysiological processes associated with PD (19). The properties of 
Mito-apocynin identified in this model strongly support potential clinical applications for Mito-apocynin 
as a viable neuroprotective and antineuroinflammatory drug for treating PD when compared to 
conventional therapeutic approaches. 
Mitochondrial toxin-based PD models such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-
hydroxydopamine (6-OHDA), and rotenone are used to screen compounds for further development. However, 
toxin-based PD models do not reflect human PD mainly due to the acute nature of neuronal injury, 
toxicant/drug interactions, and between-subject response variation (6, 21, 47). MitoPark mice were created by 
selective inactivation of mitochondrial transcription factor A (TFAM) in the nigrostriatal pathway (22). Key 
pathological features of PD such as adult onset, progressive neurodegeneration, protein inclusions, and 
progressive motor deficits ameliorated by l-3,4-dihydroxyphenylalanine (l-DOPA) have been identified in 
MitoPark mice (27), making the model ideal for testing novel mitochondria-targeted neuroprotective agents. 
A strong therapeutic potential exists for mitochondria-targeted antioxidants (MTAs) in neurodegenerative 
disorders (39). We recently demonstrated that apocynin (4-hydroxy-3-methoxyacetophenone), a plant-derived 
molecule structurally related to vanillin, and its dimer, diapocynin, are neuroprotective in the MPTP and 
LRRK2R1441G mouse models (18, 32). As an inhibitor of NOX2 activity, apocynin has been studied in various cell 
culture and animal models of PD (1, 12, 28). Although the high doses of apocynin and diapocynin (300 mg/kg) 
used in these animal studies were well tolerated, more efficacious apocynin analogs are needed. We therefore 
synthesized a series of mitochondria-targeted apocynins (conjugated to a triphenylphosphonium cation moiety 
via an alkyl chain with differing chain lengths [C2-C11 carbon atoms]). Using Mito-apo-C2, we have recently 
established that Mito-apo protected against neuroinflammation and neurodegeneration in the MPTP model 
(33). Herein, we evaluated the disease-modifying efficacy of a long-acting Mito-apo-C11 in the MitoPark model 
that recapitulates key features of PD, including mitochondrial dysfunction, microglial activation, and 
dopaminergic degeneration. Our results show that oral administration of Mito-apo dampens chronic, 
progressive behavioral deficits and dopaminergic neurodegeneration. Additional mechanistic studies support 
the enhanced mitochondrial function and anti-inflammatory properties of Mito-apo. 
Results 
Mito-apo restores mitochondrial function in dopaminergic neuronal cells 
We first assessed the effect of Mito-apo on key markers of mitochondrial bioenergetics of dopaminergic 
neuronal cells. The Seahorse extracellular flux analyzer revealed the basal respiration rate to be nearly double 
the control oxygen consumption rate (OCR) values in 10- to 30-μM Mito-apo-treated N27 dopaminergic 
neuronal cells (Fig. 1A, B). On treatment with oligomycin, Mito-apo-treated cells showed a significantly higher 
ATP-linked respiration (Fig. 1A, C) and respiratory capacity (Fig. 1A, D) than untreated cells. As expected, in the 
positive control, 1 μM rotenone abolished the OCR signal (Fig. 1A–D). 
 
 
FIG. 1. Bioenergetics and in vitro characterization of Mito-apo. (A–D) N27 cells given 10–30 μM Mito-apo for 
3 h were measured using a Seahorse XF96 analyzer. Basal respiration rate before injection (A, B). After adding 
oligomycin, ATP-linked respiration (A, C). Respiratory capacity measured as OCR after carbonilcyanide p-
trifluoromethoxyphenylhydrazone (FCCP) injection (A, D). (E–G) Mito-apo replenished ATP 
levels, (E) upregulated m-aconitase activity, (F) and decreased oxidant production in TFAM KD cells (TFAM-KD). 
TFAM-KD and control cells were incubated with 10–30 μM Mito-apo for 3 (E–F) or 12 h (G). Raw luminescence 
units of ATP produced (E). Aconitase activity (F) and mitochondrial ROS production (G) as determined by 
aconitase and MitoSOX assays. (H–J) TFAM-KD and control cells were incubated with 10–30 μM Mito-apo for 
12 h, and mitochondria were stained by MitoTracker (scale bar = 10 μm). Analysis of mitochondrial length (I) and 
degree of circularity (J). Rotenone (1 μM) was used as a positive control in all experiments. Graphical results 
represented as the mean ± SEM (n = 6 wells/group). **p < 0.01 versus control; 
***p < 0.001 versus control; #p < 0.05 versus vehicle-treated TFAM-KD cells. See also Supplementary Figures 
S1 and S6. KD, knockdown; OCR, oxygen consumption rate; ROS, reactive oxygen species; SEM, standard error of 
the mean; TFAM, mitochondrial transcription factor A. 
 
Given that knockdown (KD) of TFAM has been shown to result in cellular ATP depletion and loss of 
mitochondrial function in mammalian cell culture studies (48), we determined if Mito-apo could improve 
mitochondrial function in stable TFAM-KD N27 cells that we generated using the CRISPR/Cas9 system as 
described in Supplementary Data (Supplementary Data are available online at www.liebertpub.com/ars). 
Transduction of N27 cells with TFAM-KD resulted in >80% loss in TFAM mRNA levels relative to control cells 
(Supplementary Fig. S1). In contrast to control N27 cells, TFAM-KD cells had significantly lower cellular ATP levels 
(Fig. 1E). Rotenone (1 μM) for 3 h (positive control) dramatically decreased cellular ATP levels in control N27 
cells. Mito-apo did not significantly alter the ATP levels in control cells. However, exposure to 10–30 μM Mito-
apo for 3 h dramatically increased cellular ATP levels in TFAM-KD N27 cells, suggesting that Mito-apo replenishes 
ATP levels in mitochondrially stressed cells. 
Aconitases are iron–sulfur-containing enzymes that isomerize citrate and are inactivated during mitochondrial 
oxidative stress. Measurement of aconitase enzyme activity in TFAM-KD cells revealed significantly decreased m-
aconitase activity when compared to control N27 cells, indicating that TFAM-KD led to significant mitochondrial 
oxidative damage (Fig. 1F). However, treating the TFAM-KD cells with 10–30 μM Mito-apo for 3 h returned m-
aconitase activity to levels present in control N27 cells. Mito-apo did not significantly alter the m-aconitase 
activity in control cells, and rotenone strongly reduced m-aconitase activity in both cells (Fig. 1F). 
We also assessed the loss of mitochondrial function with MitoSOX™ red dye in TFAM-KD and control N27 cells. 
Basal oxidation of MitoSOX probe was significantly higher in TFAM-KD than in control cells (Fig. 1G). A 12-h 
exposure to 10 and 30 μM Mito-apo decreased the rate of probe oxidation in TFAM-KD, but not in control N27 
cells (Fig. 1G). As observed previously using hydroethidine probe in control N27 cells (20), rotenone strongly 
stimulated MitoSOX oxidation in both cell lines. 
MitoTracker red dye was used to visualize integrity or structural abnormalities in TFAM-KD N27 cells. Healthy 
mitochondria, such as those from control cells, appear as long, thread-like structures (Fig. 1H). Relative to those 
of control cells, the mitochondria of TFAM-KD N27 cells were significantly shorter (Fig. 1I) and more circular (Fig. 
1J), further indicating a striking loss of mitochondrial structural integrity. Although 10 μM Mito-apo was not 
enough to improve mitochondrial morphology, TFAM-KD cells treated with 30 μM Mito-apo exhibited 
significantly increased mitochondrial length (Fig. 1H, I). Collectively, results from these experiments suggest that 
Mito-apo restores mitochondrial morphology and function in TFAM-KD N27 cells. 
Mito-apo stalls progression of motor deficits 
Considering that Mito-apo was capable of replenishing mitochondrial function in TFAM-KD N27 cells, we decided 
to determine if Mito-apo is neuroprotective in the MitoPark mouse model of PD, in which TFAM is selectively 
inactivated in dopaminergic neurons. Preceded by early neurochemical alterations, these mice exhibit 
behavioral deficits by 12 weeks, which become progressively worse by 24 weeks (34). Our dose for this study 
was initially based on the severity of our model and the therapeutic efficacy reported for other model systems in 
previous publications (19, 33). Given that MitoPark is one of the most severe models of PD, we considered that 
the lower dose of Mito-apocynin used in the MPTP article (3 mg/kg/day) and LRRK2 article (3 mg/kg, 3 × /week) 
might not be sufficient in the MitoPark mice, and therefore used a higher dose. As depicted in our treatment 
paradigm (Fig. 2A), MitoPark and age-matched C57 mice were orally administered either Mito-apo (10 mg/kg, 
3 × /week) or vehicle (10% ethanol/PBS) beginning at age 13 weeks. Open-field activity and rotarod behavioral 
performances were evaluated at ages 18, 21, and 24 weeks (Supplementary Fig. S2). 
 
 
FIG. 2. Progressive motor deficits in MP mice are improved with Mito-apo. (A) Treatment schedule showing 
C57 and MP mice orally administered vehicle or Mito-apo (10 mg/kg). (B) VersaPlot showing horizontal activity 
and rearing activity (red dots) during a 10-min open-field test. Horizontal (C) and vertical (D) activities and 
distance traveled (E) during open-field test. (F) Time spent on rotarod. Graphical results represented as the 
mean ± SEM (n = 9–13 mice/group). **p < 0.01 versus control; 
***p < 0.001 versus control; ###p < 0.001 versus vehicle-treated MP. See also Supplementary Figure S2. MP, 
MitoPark. 
 
Decreased movement, as expected in 24-week MitoPark mice, is shown by representative Versaplot maps (Fig. 
2B), and improved locomotion can be seen in plots of the Mito-apo-treated MitoPark mice. Consistently, 24-
week MitoPark mice exhibited decreased horizontal activity (Fig. 2C), vertical activity (Fig. 2D), total distance 
traveled (Fig. 2E), and time spent on the rotarod (Fig. 2F). Mito-apo treatment did not have any significant effect 
on any of these behavioral parameters in age-matched control mice, but importantly, the horizontal and vertical 
activity levels and rotarod performance of MitoPark mice were significantly retained by Mito-apo treatment in 
contrast to vehicle-treated MitoPark mice. 
Mito-apo treatment dampens nigrostriatal tyrosine hydroxylase neuronal loss and 
striatal DA depletion 
Neurodegeneration in the SN is progressive and severe in aged MitoPark mice (27). Brain sections from 24-week 
MitoPark mice were immunostained for tyrosine hydroxylase (TH) to detect dopaminergic neurons. A significant 
loss of TH+ cell bodies and terminals in the SN and striatum, respectively, occurred in vehicle-treated 24-week 
MitoPark mice (middle panel) in contrast to vehicle-treated age-matched C57 mice (top panel) (Fig. 3A). DAB 
immunostaining showed significantly higher levels of TH immunoreactivity (Fig. 3A) and neuronal counts (Fig. 
3B) in the striatum and SN of Mito-apo-treated MitoPark mice compared to vehicle-treated MitoPark mice. 
Mito-apo did not alter the number of TH neurons in control mice. Further confirmation came from Western 
blots and their densitometric analysis, where higher levels of TH protein expression were observed in the SN of 
Mito-apo-treated MitoPark mice versus vehicle-treated MitoPark mice (Fig. 3C). Full Western blots from cropped 
images in all figures can be found in Supplementary Fig. S3. 
 
 
FIG. 3. Neurodegeneration and dopamine depletion in MP mice are attenuated by Mito-apo. DAB 
immunostaining (A) in striatum and SN (scale bars = 1 mm and 100 μm) of vehicle-treated C57 (top), vehicle-
treated MP (middle), and Mito-apo-treated MP mice (bottom). (B) Stereological cell counts of TH+ neurons in the 
SN of n = 3/group. (C) Representative Western blot of two animals/group and densitometric analysis of TH 
protein levels normalized to β-actin in the SN (n = 6/group). High-performance liquid chromatography with 
electrochemical detection was used for determination of dopamine (D), DOPAC (E), and HVA (F). Graphical 
results represented as the mean ± SEM (n = 6–8 mice/group). ***p < 0.001 versus vehicle-treated C57; #p < 0.05, 
or ###p < 0.001 versus vehicle-treated MP. DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; SN, 
substantia nigra; TH, tyrosine hydroxylase. 
 
Since Mito-apo-treated MitoPark mice had more dopaminergic neurons remaining in the SN, we performed 
high-performance liquid chromatography (HPLC) with electrochemical detection to determine if striatal levels of 
DA and its metabolites were also protected. We observed a severe loss of DA, DOPAC, and HVA, respectively, in 
the striatum of vehicle-treated MitoPark mice compared to age-matched control mice (Fig. 3D–F). In contrast, 
Mito-apo increased DA and DOPAC by 2.6- and 2.0-fold, respectively, when compared to vehicle-treated 
MitoPark mice. Mito-apo did not affect striatal DA and its metabolite levels in C57 black mice. Together, these 
data suggest that Mito-apo substantially increases the TH neuronal cell count and striatal DA levels in aged 
MitoPark mice. 
Mito-apo attenuates mitochondrial aconitase inactivation and oxidative damage 
To further determine the effect of Mito-apo on mitochondrial redox status in the MitoPark model, we used ex 
vivo electron paramagnetic resonance (EPR) analysis to see if Mito-apo protects against inactivation of 
mitochondrial aconitase. Previously, we had shown that Mito-Q10 treatment mitigates MPTP-mediated 
inactivation of mitochondrial aconitase and inhibits the increase in the EPR signal intensity at g′ = 6 (attributed 
to cytochrome c) detected in brain tissues obtained from MPTP-treated mice (31). Similarly, in this study, we 
show that the EPR spectra in the g ∼ 2 region (blue bracket, Fig. 4A) from MitoPark striatal samples (middle 
spectra, Fig. 4B) have higher fractional intensities, which are primarily due to the inactive, oxidized [3Fe–
4S]+ cluster of aconitase. EPR spectral signals were internally normalized to high-spin heme (blue arrow, Fig. 4A, 
C). A similar trend occurred in cortical tissues, but was insignificant (Supplementary Fig. S4). Most importantly, 
Mito-apo treatment significantly reduced the fractional intensities from the [3Fe–4S]+ cluster signal in MitoPark 
mice relative to vehicle treatment (Fig. 4D). 
 
 
FIG. 4. Mitochondrial aconitase inactivation and oxidative stress are attenuated in Mito-apo-treated MP mice. 
(A) The g ∼ 2 region (blue bracket) and HS heme (arrow, internal control) of the experimental EPR spectra from 
the pooled striatum (each spectrum represents 3–5 combined animal tissues) from vehicle-treated C57 (top), 
vehicle-treated MP (middle), and MP mice treated with 10 mg/kg Mito-apo from 13 to 24 weeks of age 
(bottom). The spectra are primarily due to the oxidized [3Fe–4S] cluster of aconitase (∼3330 G), and the reduced 
N2 (3370 G), N4 (3485 G), and N3 (3540 G) complex I iron–sulfur complexes, although other components 
underlie these species, and fits to all components were used to estimate the relative contributions to the 
spectra (fits are presented under each of the three experimental traces, respectively, in A). (B) Expansion of 
the g ∼ 2 region. Fractional intensities from EPR spectra in the g ∼ 2 region normalized to combined tissue 
weight (C) and internally normalized to the HS-heme group (D). (E) Twenty-four-week mouse tissues of vehicle-
treated C57 (top), vehicle-treated MP (middle), and Mito-apo-treated MP mice (bottom) were double 
immunostained for TH and 4-HNE (scale bar = 10 μm). Merged MP image shows colocalization of TH and 4-HNE 
in DAergic neurons. (F) Representative Western blot and densitometric analysis of 4-HNE protein in the SN 
(n = 6/group). *p < 0.05 versus C57; #p < 0.05 versus vehicle-treated MP. See also Supplementary Figure S4. EPR, 
electron paramagnetic resonance; 4-HNE, 4-hydroxynonenal. 
 
Oxidative damage biomarkers such as nitrotyrosine-containing proteins and lipid peroxidation product 4-
hydroxynonenal (4-HNE) have been shown in animal models of PD and have high correlation to disease states 
(32, 51). Confocal imaging of immunohistochemistry (IHC) double labeled with TH antibody and Western blot 
analysis revealed increased 4-HNE expression in the SN of aged MitoPark mice but not in control mice (Fig. 4E, 
F). Mito-apo administration almost completely suppressed 4-HNE levels in the SN of aged MitoPark mice. These 
results demonstrate that Mito-apo attenuates mitochondrial aconitase inactivation in the striatum and oxidative 
damage in nigral neurons of aged MitoPark mice. 
Mito-apo inhibits microglia activation in the SN 
Neuroinflammation is now recognized to play a key role in dopaminergic neurodegeneration in human PD 
patients and in mouse models (17, 53, 66). Although mitochondrial dysfunction and oxidative stress act as key 
players in the progressive degenerative MitoPark mouse model, the presence of neuroinflammation in this 
model has not yet been explored. Western blotting and DAB immunostaining show that IBA1 expression 
increases in the SN of MitoPark mice (Fig. 5A, B). However, levels of the IBA1 protein were significantly lower in 
Mito-apo-treated MitoPark mice. IBA1 DAB immunostaining (Fig. 5B) revealed an increased number of microglia 
in the aged, vehicle-treated MitoPark SN, and at higher magnification, increased soma size and fewer processes, 
indicating an activated phenotype. These features occurred to a much lesser extent in the Mito-apo-treated 
MitoPark mice. Indeed, the cell count per field (Fig. 5C) was significantly lower in the Mito-apo-treated group, 
average soma size was smaller (Fig. 5D), and ImageJ skeleton analysis revealed more process endpoints per cell 
in Mito-apo-treated MitoPark mice when compared to vehicle-treated MitoPark mice (Fig. 5E). Other variables 
indicative of a normal microglia phenotype, such as the number of branches, number of junctions, and the 
longest-shortest path, were significantly reduced in the MitoPark group when compared to controls (Fig. 5F–H). 
However, the MitoPark mice treated with Mito-apo did not exhibit significant microglial morphological changes 
when compared to age-matched control mice. We also observed CD68+ staining, a marker of microglia 
activation, in vehicle-treated MitoPark mice that was not present in control or Mito-apo-treated MitoPark mice 
(Supplementary Fig. S5). 
 
 
FIG. 5. Mito-apo inhibits microglia activation in the SN of MP mice. (A) Western blot and densitometric analysis 
of IBA1 protein in the SN (n = 6/group). (B) IBA1 DAB immunostained sections from 24-week mouse SN of 
vehicle-treated C57 (left), vehicle-treated MP (middle), and Mito-apo-treated MP mice (right) showing microglia 
morphology (scale bar = 200 μm). ImageJ analysis of microglia for cells per field (C), soma size (D), number of 
endpoints per cell (E), number of branches per cell (F), number of junctions per cell (G), and longest-shortest 
path (H). Graphical results represented as the mean ± SEM (n = 5–7 mice/group). *p < 0.05 versus C57 control; 
**p < 0.01, ***p < 0.001 versus vehicle-treated C57; #p < 0.05 versus vehicle-treated 
MP; ##p < 0.01 versus vehicle-treated MP; ###p < 0.001 versus vehicle-treated MP. See also Supplementary Figure 
S5. 
 
Mito-apo decreases NOX2 and iNOS activity in microglia 
An increase in NOX2 and iNOS expression during microglial activation may synergistically contribute to neuronal 
death (46). Since Mito-apo treatment inhibits microglia activation, we then tested whether it also dampened 
NOX2 activity and iNOS induction. Immortalized microglial cells were generated as described in the Materials 
and Methods section and obtained as a kind gift from Dr. Douglas Golenbock for conducting the following 
experiments (37). To better define the therapeutic target of Mito-apo in microglia, we examined NOX2 
activation by p47phox translocation from cytosol to the membrane. Western blot analysis revealed that 
lipopolysaccharide (LPS) robustly increased the amount of membrane-bound p47phox in microglia, while the 
cytosolic p47phox was significantly reduced when compared to control cells (Fig. 6A). Furthermore, this is 
substantiated by immunocytochemical results showing increased colocalization of p47phox with cholera toxin 
subunit B (CTXB-555), a membrane marker, following LPS treatment (Fig. 6B). LPS-stimulated microglia cotreated 
with Mito-apo showed a significant decrease in membrane p47phox and an increase in cytosolic p47phox when 
compared to vehicle-treated LPS-stimulated microglia (Fig. 6A). Similarly, reduced colocalization of p47phox and 
CTXB-555 was observed in Mito-apo-treated LPS-stimulated microglia (Fig. 6B). Together, these data suggest 




FIG. 6. Mito-apo decreases NOX2 and iNOS activity in microglia. (A) Western blot and accompanying 
densitometric analysis of membrane and cytosolic fractions from control and LPS-stimulated microglia treated 
with or without 10 μM Mito-apo. (B) Immunocytochemistry revealing increased membrane colocalization of 
p47phox upon LPS stimulation that is reduced with Mito-apo treatment. CTXB = cholera toxin subunit B with 555 
fluorophore. (C) ATRA-differentiated HL60 cells were pretreated with Mito-apo for 30 min in HBSS 
supplemented with HEPES buffer (25 mM, pH 7.4) and DTPA (0.1 mM), followed by the addition of the probe 
and PMA (1 μM). The slope of the fluorescence intensity monitored over 2 h was used to measure the probe 
oxidation rate. (D) Nitric oxide production from microglia as estimated in supernatant by Griess assay of nitrite 
levels. (E) LPS-induced oxidation of o-MitoPhB(OH)2 to o-MitoPhOH in microglia was inhibited by Mito-
apo. (F) Luminex multiplex assay showing levels of TNF-α, IL-1β, IL-6, and IL-12 in supernatant from LPS-
stimulated microglia (n = 4–6/group). Graphical results represented as the mean ± SEM (n = 3/group). 
*p < 0.05 versus C57 control. **p < 0.01, ***p < 0.001 versus control; #p < 0.05, ##p < 0.01, ###p < 0.001 versus LPS. 
See also Supplementary Figure S7. ATRA, all-trans retinoic acid; IL, interleukin; LPS, lipopolysaccharide; PMA, 
phorbol myristate acetate; TNF-α, tumor necrosis factor α. 
 
Our previous publication shows that HL60 cells differentiated into neutrophils and treated with phorbol 
myristate acetate (PMA) can be used as a reliable source of endogenous NOX2 activation (73). To test the effect 
of Mito-apo treatment on NOX2 activity in intact cells, we used all-trans retinoic acid (ATRA)-differentiated HL60 
cells, stimulated with PMA. We utilized hydropropidine (HPr+) as the probe for NOX2-derived superoxide radical 
anion (O2•−) and coumarin boronic acid (CBA) as a probe for hydrogen peroxide (H2O2) (73, 75). The 30-min 
pretreatment of cells with a low micromolar concentration (<10 μM) of Mito-apo led to a dose-dependent 
inhibition of the PMA-stimulated generation of O2•− and H2O2 (Fig. 6C). This demonstrates that Mito-apo directly 
or indirectly mitigates NOX2 activity. 
Next, we tested the effect of Mito-apo on oxidant production in microglial cells. After exposing microglial cells to 
LPS (1 μg/ml) for 12 h in the presence or absence of Mito-apo (10–30 μM), Griess assay revealed that Mito-apo 
completely blocked LPS-induced nitric oxide production (Fig. 6D). In addition, LC-MS-based monitoring of the 
conversion of the o-MitoPhB(OH)2 probe into the phenolic product (o-MitoPhOH) (10, 11, 74, 75) indicates 
significant suppression of mitochondrial oxidant levels (Fig. 6E). The Mito-apo cotreatment also significantly 
attenuated LPS-induced increases in the levels of supernatant cytokines, including tumor necrosis factor α (TNF-
α), interleukin-1β (IL-1β), IL-12, and IL-6, as measured by Luminex multiplex immunoassay (Fig. 6F). For 
comparison, 10 μM vitamin C and 10 μM apocynin were also tested, but neither treatment significantly 
attenuated LPS-stimulated neuroinflammation endpoints at this dose (Supplementary Fig. S6). 
Mito-apo attenuates iNOS and NOX2 expression in the SN of MitoPark mice 
Consistent with our in vitro results, double immunolabeling experiments confirmed that the increased iNOS 
expression occurred in IBA1+ microglia and was significantly reduced in Mito-apo-treated MitoPark mice (Fig. 
7A). Western blotting revealed an increase in iNOS expression in the SN of 24-week MitoPark mice that was 
significantly attenuated in the Mito-apo-treated mice (Fig. 7B). In addition, gp91phox, a subunit of NOX2, was 
upregulated in microglia of the SN of aged MitoPark mice (Fig. 7C, D), yet was significantly reduced in the Mito-
apo-treated group, as evidenced by Western blotting and IHC double labeling with IBA1. 
 
 
FIG. 7. Mito-apo inhibits iNOS and NOX2 expression in the SN of MP mice. Determination of NOX2 and iNOS 
activity in the SN. (A) Twenty-four-week mouse tissues of vehicle-treated C57 (top), vehicle-treated MP (middle), 
and Mito-apo-treated MP mice (bottom) stained for IBA1 and iNOS (scale bar = 10 μm). Merged MP image shows 
colocalization (arrow) of IBA1 and iNOS in SN tissues. (B) Representative Western blot and densitometric 
analysis of iNOS protein in the SN (n = 6/group). (C) IHC for IBA1 and gp91phox of vehicle-treated C57 (top), 
vehicle-treated MP (middle), and Mito-apo-treated MP mice (bottom). Merged MP image shows colocalization 
(arrows) of IBA1 and gp91phox in SN tissues. (D) Representative Western blot and densitometric analysis of 
gp91phox protein in the SN (n = 6/group). (E) IHC for TH and 3-nitrotyrosine of vehicle-treated C57 (top), vehicle-
treated MP (middle), and Mito-apo-treated MP mice (bottom). Graphical results represented as the 
mean ± SEM. #p < 0.05 versus vehicle-treated MP; *p < 0.05 versus vehicle-treated C57; 
***p < 0.001 versus vehicle-treated C57; IHC, immunohistochemistry. 
 
Given that the NOX4 isoform has been shown to localize in the mitochondria of neurons (7), we also assessed 
whether Mito-apo alters NOX4 in our mitochondrially defective cell and animal models of PD. In TFAM-KD N27 
dopaminergic cells, NOX4 levels increased significantly when compared to control cells (Supplementary Fig. 
S7A). However, Mito-apo treatment did not alter NOX4 levels in TFAM-KD cells. Furthermore, NOX4 mRNA and 
protein levels were not altered in the SN of either MitoPark mice or MitoParks treated with Mito-apo when 
compared to age-matched control mice (Supplementary Fig. S7B, C). These data suggest that Mito-apo is more 
selective for NOX2 over NOX4 in neuronal cells and NOX4 is not a major contributor to oxidative damage in the 
MitoPark model. 
Peroxynitrite, formed when superoxide reacts with nitric oxide, nitrates tyrosine residues on proteins and 
contributes to neuronal cell death (33, 75). Increased nitrative modification was evidenced by higher 3-NT 
expression in the SN of 24-week MitoPark mice compared to C57 black mice (Fig. 7E). Notably, 3-NT expression 
was significantly suppressed in Mito-apo-treated MitoPark mice. Overall, these data show that Mito-apo 
attenuated microglia activation and neuronal cell death in MitoPark mice by suppressing oxidative and nitrative 
stress. 
Mito-apo is central nervous system bioavailable without systemic adverse effects 
Finally, we determined if Mito-apo reaches its target brain tissues, the SN and striatum. Mice were orally 
administered Mito-apo (10 mg/kg), sacrificed, and tissues were harvested at 30 min, 3, 6, 12, 24, and 48 h. 
Striatal and nigral regions were processed for HPLC. Here, we have provided evidence that Mito-apo reaches its 
target brain tissues, the SN and striatum, and did not cause systemic adverse effects (Supplementary Fig. 
S8 and Tables 1 and and2).2). LC MS/MS analysis did not detect the Mito-apo in extra-nigral tissues. We also 
conducted a dose–response study at the 6-h time point, when Mito-apo availability peaks in brain tissues 
(Supplementary Fig. S8), yet did not detect any significant difference between 10 and 30 mg/kg Mito-apo oral 
administration. 
  
Table 1. clinical pathology results for mice (n = 3) 3 hour postoral gavage with 10 mg/kg mito-apo-c11 using the abaxis system 
      3-h Control    3-h Mito-apo-C11    
Parameter Units p Mean Min Max SD Mean Min Max SD 
Albumin g/dl 0.31 3.23 2.40 3.90 0.62 3.77 3.50 4.00 0.21 
Alkaline phosphatase IU/L 1.00 70.67 56.00 88.00 13.20 70.67 63.00 81.00 7.59 
ALT IU/L 0.41 65.67 38.00 84.00 19.91 94.00 54.00 146.00 38.51 
Amylase U/L 0.38 1061.33 927.00 1316.00 180.17 1699.00 1050.00 2977.00 903.72 
Total bilirubin U/L 0.37 0.30 0.30 0.30 0.00 0.33 0.30 0.40 0.05 
BUN mg/dl 0.83 15.33 12.00 21.00 4.03 14.67 13.00 16.00 1.25 
Calcium mg/dl 0.50 11.73 11.50 12.20 0.33 11.50 11.20 11.90 0.29 
Phosphorous mg/dl 0.94 10.20 8.50 12.20 1.53 10.30 9.50 11.80 1.06 
Creatinine mg/dl 0.37 0.27 <0.20 0.40 0.09 0.20 <0.20 <0.20 0.00 
Glucose mg/dl 0.05 292.33 274.00 317.00 18.12 336.67 320.00 352.00 13.10 
Sodium mEq/L 0.84 159.00 156.00 161.00 2.16 159.33 159.00 160.00 0.47 
Potassium mEq/L 1.00 8.50 >8.50 >8.50 0.00 8.50 >8.50 >8.50 0.00 
Total protein g/dl 0.81 5.50 5.40 5.60 0.08 5.53 5.30 5.70 0.17 
 
Table 2. clinical pathology results for mice (n = 3) 48 hour postoral gavage with 10 mg/kg mito-apo-c11 
      48-h Control    48-h Mito-apo-C11    
Parameter Units p Mean Min Max SD Mean Min Max SD 
Albumin g/dl 0.23 4.07 3.70 4.40 0.29 4.37 4.30 4.50 0.09 
Alkaline phosphatase IU/L 0.02 134.00 119.00 159.00 17.80 82.00 72.00 91.00 7.79 
ALT IU/L 0.20 60.33 45.00 77.00 13.10 90.33 58.00 118.00 24.72 
Amylase U/L 0.05 858.33 816.00 935.00 54.31 1024.00 962.00 1118.00 67.59 
Total bilirubin U/L 0.52 0.37 0.30 0.40 0.05 0.33 0.30 0.40 0.05 
BUN mg/dl 0.15 14.67 13.00 18.00 2.36 17.67 17.00 18.00 0.47 
Calcium mg/dl 0.02 10.73 10.50 11.00 0.21 11.40 11.20 11.60 0.16 
Phosphorous mg/dl 0.01 8.30 8.10 8.50 0.16 10.03 9.40 10.40 0.45 
Creatinine mg/dl 1.00 0.20 0.20 0.20 0.00 0.20 0.20 0.20 0.00 
Glucose mg/dl 0.06 227.67 196.00 250.00 23.01 271.67 261.00 282.00 8.58 
Sodium mEq/L 0.14 159.00 156.00 161.00 2.16 162.00 161.00 163.00 0.82 
Potassium mEq/L 0.37 8.40 8.20 8.50 0.14 8.50 8.50 8.50 0.00 
Total protein g/dl 0.12 5.17 4.90 5.50 0.25 5.53 5.40 5.60 0.09 
 
  
Clinical pathology can be particularly useful in predicting toxicity in animal models for preclinical evaluation 
(5, 59). Blood plasma, collected by cardiac puncture at 3 and 48 h after gavaging mice with 10 mg/kg Mito-apo, 
was analyzed using the Abaxis system. Clinical pathology variables are reported in Tables 1 and and2.2. At 3 h, 
the only significant difference between vehicle and Mito-apo-treated C57 black mice was blood glucose level 
(Table 1). As mice were not fasted, the range of values for both groups is considered acceptable (57). Alkaline 
phosphatase (ALP) levels, an indicator of hepatobiliary or bone disease, were significantly less in Mito-apo-
treated mice than in controls after 48 h (Table 2), but still within normal reference intervals. Calcium and 
phosphorous levels were elevated in the Mito-apo-treated group, but no other significant changes were 
observed at 48 h postgavage. These results suggest that Mito-apo can rapidly cross the blood–brain barrier and 
persist in the central nervous system (CNS) to produce its neuroprotective effect without contributing to any 
major acute adverse effects. 
Discussion 
Oxidative stress, mitochondrial dysfunction, and neuroinflammation contribute to dopaminergic degeneration in 
PD (3, 13, 66). Reactive oxygen species (ROS) derived from NOX2 and mitochondria potentiate 
neurodegeneration through oxidative stress and promote proinflammatory events (12, 56). In this study, we 
tested a recently created pharmacophore, Mito-apo, in cell culture and animal models of mitochondrial 
dysfunction and neuroinflammation. First, Mito-apo treatment increased OCR in a dopaminergic cell line, 
indicating a bioenergetic effect. This was further clarified by showing that treatment with Mito-apo increased 
aconitase activity and ATP levels, improved mitochondrial structural integrity, and decreased mitochondrial 
oxidants in TFAM-KD N27 cells. In MitoPark mice, Mito-apo treatment attenuated progressive motor deficits, 
striatal neurotransmitter depletion, and nigrostriatal degeneration, suggesting a neuroprotective property. 
Mito-apo treatment also prevented microglial activation, proinflammatory mediators, NOX2 and iNOS 
activation, and oxidative stress marker formation. Thus, our data demonstrate anti-inflammatory, antioxidant, 
and neuroprotective properties of a new apocynin derivative, Mito-apo, in MitoPark mice that possess 
pathological features of chronic dopaminergic neurodegeneration, including mitochondrial dysfunction, 
oxidative damage, and neuroinflammation. 
Mitochondrial dysfunction can be found in toxin-based models, such as the MPTP and 6-OHDA treatment 
paradigms, and in genetic models, such as the LRRK2- and PINK1-based models (3, 16, 44, 62, 71). Wang et 
al. (69) demonstrated that TFAM inactivation results in respiratory chain deficiency and increased in 
vivo apoptosis, and proposed that the resulting loss of mitochondrial function has important therapeutic 
implications for human disease. Although the MitoPark model, with TFAM knocked out in the nigrostriatal 
pathway, does not mirror any specific genetic mutation associated with PD, both TFAM and mitochondrial DNA 
changes have been implicated in aging and PD (2, 29, 30, 54). Similarly, the TFAM-KD N27 dopaminergic cells 
generated using the CRISPR/Cas9 system manifested mitochondrial dysfunction as reduced m-aconitase activity 
and ATP levels, increased oxidant production, and altered mitochondrial morphology. Our results clearly indicate 
that Mito-apo restores functional mitochondria by increasing mitochondrial bioenergetics and inhibiting 
production of oxidants. Thus, treatment with an MTA can alleviate the loss of mitochondrial structural and 
functional integrity in a cell culture model of mitochondrial dysfunction. 
We next determined if Mito-apo exerts its protective action on mitochondrial redox in vivo. To gain insights into 
any effect of Mito-apo on oxidative stress amelioration in MitoPark mice, we monitored the EPR signals due to 
mitochondrial aconitase iron–sulfur clusters in brain tissue at cryogenic temperatures. ROS-induced oxidation of 
the catalytically required [4Fe–4S]2+ cluster inactivates the aconitase enzyme due to loss of the labile iron ion, 
forming the EPR detectable [3Fe–4S]+ cluster. Mito-apo treatment significantly inhibited the development of the 
[3Fe–4S]+ cluster EPR signal from mitochondrial aconitase in MitoPark mice. These results suggest that Mito-apo 
treatment can effectively block m-aconitase inactivation in aged MitoPark mice. Advancing age is a main risk 
factor in neurodegenerative disease and is correlated with increased mitochondrial dysfunction and oxidative 
stress, leading to irreversible structural changes in proteins, lipids, and DNA (51, 65, 68). Here we found that 
levels of 4-HNE-modified proteins, an unsaturated aldehyde generated during lipid peroxidation and marker of 
oxidative damage, were significantly higher in the SN of 24-week MitoPark brains compared to age-matched C57 
black controls, yet Mito-apo treatment significantly decreased these levels. Hence, oxidative stress associated 
with the inherent mitochondrial dysfunction in the MitoPark model can be reduced by long-term, low-dose 
treatment with Mito-apo. 
In the CNS, microglial activation and the production of proinflammatory factors, including cytokines, ROS, and 
RNS, are hallmarks of inflammatory reactions. Our IHC and Western blot analyses revealed significantly 
increased IBA1 expression in the SN of 24-week MitoPark mice coupled with increased soma size and fewer 
processes, suggesting increased microglia activation in 24-week MitoPark mice. Mito-apo-treated MitoPark mice 
had significantly fewer IBA1+ cells, decreased soma size, and increased branching complexity consistent with 
ramified microglia when compared to vehicle-treated MitoPark mice. Mito-apo treatment also effectively 
decreased iNOS and gp91phox protein levels in the IBA1+ nigral cells of MitoPark mice. Activation of NOX2 and 
mitochondrial ROS signaling was proposed to involve crosstalk that increases production of both in a feed-
forward cycle (15, 46). NOXs play an obvious role in dopaminergic neurodegeneration via ROS generation 
(9, 52). However, their involvement in PD is potentially more complex, involving other contributing factors such 
as protein aggregation and mitochondrial dysfunction (13, 15, 20). In animal models of PD in which 
proinflammatory enzymes are elevated, anti-inflammatory therapies have successfully modulated the 
neurodegenerative process (32, 56). Reactive microgliosis results from stressed neurons secreting factors that 
activate microglia, beginning the cycle of neuroinflammation and neuronal damage underlying 
neurodegenerative diseases (4, 42, 45). Although neuroinflammation was not originally defined in the MitoPark 
model, we show here that reactive microgliosis is likely involved, implicating an important therapeutic potential 
for MTA and anti-inflammatory drugs in PD. This finding is salient considering that chronic neuroinflammation is 
now perceived to mediate PD pathogenesis and current drugs only provide symptomatic relief (60, 66). 
By restricting p47phox from translocating to the membrane and subsequently inhibiting superoxide production by 
NOX2 in microglia, Mito-apo reduced inflammation in addition to its role as an antioxidant in neurons. This 
combined effect on both microglia and neurons may help to break up a self-propelling cycle of 
neuroinflammation and neurodegeneration characteristic of PD. This approach was also recently found to be 
effective in the toxin-based MPTP model (28). It should be noted that the severity of the MitoPark model 
allowed for only a modest recovery of motor function with Mito-apo treatment due to the complex nature of 
the neurodegenerative process. We explored the potential benefit of a higher dose by performing a dose–
response study at the time point with the highest concentration of Mito-apo in the brain (Supplementary Fig. 
S3D). However, our results did not show significantly more Mito-apo detectable in brain tissues of the 30 mg/kg 
group versus 10 mg/kg group. This suggests that even at a higher dose, Mito-apo would not have provided an 
additional benefit. Additional analysis of Mito-apo by LC-MS/MS did not detect the compound, but spiking the 
samples with 0.1 μM concentration detected the peak. A detailed pharmacokinetic analysis of Mito-apo is still 
warranted. Although oxidative stress and neuroinflammation are key players in the cell death mechanisms 
leading to PD, other mechanisms such as protein aggregation, ubiquitin–proteasome system dysfunction, 
mitophagy, and inflammasome-dependent neuroinflammation have not yet been fully addressed in this model 
or with this compound. Furthermore, our group and others have shown that targeting a single 
pathophysiological pathway is not typically enough to completely restore function in the MitoPark model 
(24, 41). These observations warrant future studies into the therapeutic role of Mito-apo and the development 
of combination therapy modalities for PD. 
Recently, we have demonstrated that Mito-apo prevents hyposmia and motor deficits in the LRRK2 mouse 
model (19). However, the effect of Mito-apo on mitochondrial function, microglial activation, NOX2 activation, 
and dopaminergic degeneration was not directly investigated in that model. Although circadian and cognitive 
changes occur in MitoPark mice (25, 43), the nonmotor Parkinsonian phenotype of these mice still needs to be 
fully characterized. Moreover, Mito-apo efficacy in treating nonmotor symptoms in PD animal models should be 
evaluated since antioxidants have been shown to successfully improve cognitive and neuropsychiatric symptoms 
in various neurodegenerative models (64, 67). 
Based on our findings using a progressively degenerating and mitochondrially dysfunctional animal model of PD, 
Mito-apo may outperform other experimental drugs by being well tolerated yet bioavailable in the brain when 
delivered orally, and by exhibiting potent antineuroinflammatory and antioxidant effects at a low dose. Here we 
have demonstrated that Mito-apo protected dopaminergic neurons and reduced oxidative and nitrative stress, 
glial cell activation, and inflammatory reactions. NOX2-mediated superoxide production is thought to be 
essential for maintaining chronic neuroinflammation, which potentiates the neurodegenerative process through 
oxidative stress (9, 52). NOX2 knockout or treatment with NOX2 inhibitors in cell culture and mouse studies 
suggests that inhibiting NOX2 breaks the vicious, self-propelling cycle of reactive microgliosis, making it a 
valuable target for PD therapy (61, 70). These properties strongly support potential clinical applications for Mito-
apo as a viable neuroprotective and antineuroinflammatory drug for treating PD when compared to 
conventional therapeutic approaches that only target downstream consequences of microglia activation and 
inflammation-mediated oxidative stress. Overall, we demonstrate that Mito-apo treatment effectively 
attenuates progressive motor deficits, neuroinflammation, neurochemical depletion, and loss of nigral TH 
neurons, revealing a neuroprotective effect in a comprehensive PD model that recapitulates salient features of 
chronic progressive dopaminergic neurodegeneration. Our proof-of-principle preclinical study warrants further 
translation of Mito-apo to preclinical safety evaluations and to subsequent clinical testing. 
Materials and Methods 
Chemicals 
Rotenone (R8875), oligomycin (75351), antimycin A (A8674), dopamine hydrochloride (H8502), 3-4-
dihydroxyphenylacetic acid (DOPAC, 850217), homovanillic acid (HVA, H1252), 3,3′-diaminobenzidine (DAB, 
D5637), Griess reagent (4410), puromycin (P8833), and hydrogen peroxide (H325) were all purchased from 
Sigma (St. Louis, MO). The CellTiter-Glo Cell Viability assay kit (G5421) was bought from Promega (Madison, WI). 
We purchased RPMI 1640 (11875093), Dulbecco's modified Eagle's medium (DMEM) (11330), fetal bovine serum 
(FBS, 26140), l-glutamine (25030081), penicillin–streptomycin (15140122), MitoTracker red (M-7512), and 
MitoSOX (M36008) from Invitrogen (Carlsbad, CA), and the Seahorse Flux Pak calibration solution and 
carbonilcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (103015) from Seahorse Biosciences (Billerica, MA). 
The aconitase assay kit (ab83459), anti-4-HNE (mab3249), anti-IBA1 (ab5076), and gp91phox (ab129068) 
antibodies were purchased from Abcam (Cambridge, MA). Anti-NOS2 (sc-650) and p47phox (H-195) antibodies 
were obtained from Santa Cruz Biotech (Dallas, TX), anti-IBA1 antibody (019-19741) was purchased from Wako 
(Richmond, VA), and anti-TH (mab318) and anti-3-NT (06-284) antibodies were purchased from Millipore 
(Billerica, MA). 
Mito-apocynin synthesis 
Mito-apo-C2 and Mito-apo-C11 were synthesized as described previously (19). Briefly, acetylvanillic acid and 
thionyl chloride were mixed to form acetylvanillic acid chloride, which was dissolved in dichloromethane and 
amino alkyl triphenyl phosphonium bromide and pyridine. The solution was purified on a silica gel column and 
the acetyl group was removed by hydrolysis. 
Cell culture and CRISPR/Cas-based knockout of TFAM in N27 cells 
For in vitro mitochondrial function studies, the rat immortalized mesencephalic dopaminergic neuronal cell line 
(1RB3AN27 or N27) was cultured in RPMI 1640 containing 2 mM l-glutamine, 50 U of penicillin, and 50 μg/ml of 
streptomycin with 0–10% FBS in incubators at 37°C and 5% CO2 as previously described by our laboratory (8). 
The lentivirus-based CRISPR/Cas9 KO plasmid, pLV-U6gRNA-Ef1aPuroCas9GFP-TFAM, with the TFAM gRNA 
target sequence directed against the exon 1 sequence (CPR555e5e4099bf84.98), was purchased from Sigma-
Aldrich. To make lentivirus, the lenti-CRISPR/Cas9 TFAM KO plasmid and control plasmid were transfected into 
293FT cells using the Mission Lentiviral Packaging Mix (SHP001; Sigma-Aldrich) according to the manufacturer's 
instructions. The lentivirus was harvested 48 h post-transfection and titers were measured using the Lenti-X™ 
p24 Rapid Titer Kit (632200; Clontech, Mountain View, CA). For stable KD of TFAM in N27 cells, six-well plates 
containing 0.1 × 106/well had lentivirus added the following morning to the media at an MOI of 100. After 24 h, 
fresh media supplemented with puromycin (50 μg/ml) was added to the cells for stable cell selection. 
The wild-type microglial cell line, obtained as a kind gift from Dr. Golenbock at the University of Massachusetts, 
was used for neuroinflammation experiments and cultured in DMEM containing 2 mM l-glutamine, 50 U of 
penicillin, and 50 μg/ml of streptomycin with 2% FBS in six-well plates at a density of 1.5 × 106/well. The cell line 
was immortalized from wild-type C57 mouse primary microglia by infection with J2 recombinant retrovirus 
microglia and has been characterized by Halle et al. (37). 
Mitochondrial oxygen consumption 
The Seahorse XF96 analyzer was used to monitor basal OCR in N27 dopaminergic neuronal cells at different 
stages as previously described (8). Briefly, after pre-equilibrating the cartridge containing the mito-stressors 
oligomycin (1 μg/ml), FCCP (1 μM), and antimycin A (10 μM) in injection ports, a plate with cells pretreated in 
serum-free media for 3 h with 0, 10, or 30 μM Mito-apo-C2 and 1 μM rotenone was placed into the Seahorse 
analyzer. OCR readouts were measured in pmol/min. 
Cell viability, aconitase, and NOX2 activity 
The CellTiter-Glo Luminescent Cell Viability (used to measure intracellular ATP levels) and aconitase activity 
assays were performed as per the manufacturer's instructions using control and TFAM stable KD N27 cells or 
microglia. The CellTiter-Glo Luminescent Cell Viability assays were performed using control or TFAM stable KD 
N27 cells (0.8 × 104/well) in a white opaque-walled 96-well plate. 
For the aconitase activity assay, 1 × 106 cells were plated in a T25 flask. After treatments, mitochondrial fractions 
were collected and lysed as per the manufacturer's instructions. Readings at 450 nm were obtained using a 
SpectraMax plate reader and normalized to protein concentrations determined by Bradford assay. 
NADPH oxidase activity was determined in differentiated human acute promyelocytic leukemia (dHL60) cells, as 
recently reported (73, 75). Hydropropidine probe (20 μM), in the presence of DNA (0.1 mg/ml), was used to 
monitor superoxide production, while coumarin boronic acid (100 μM) was used to monitor H2O2 formation. 
HL60 cells were maintained and differentiated with ATRA (1 μM) for 5 days as described previously (73). The 
differentiated cells were pretreated with Mito-apo for 30 min in HBSS supplemented with HEPES buffer (25 mM, 
pH 7.4) and DTPA (0.1 mM), followed by the addition of the probe and PMA (1 μM). Immediately after addition 
of PMA, the plates were placed in the plate reader and fluorescence intensity monitored over 2 h. The slope of 
the fluorescence intensity over time was used to measure the probe oxidation rate. The rate of probe oxidation 
in samples treated with pure DMSO (0.1% vol/vol) was taken as 100%. 
Oxidation of mitochondrial boronate probe 
Mitochondria-targeted boronates were proposed for site-specific detection of mitochondrial H2O2 (10, 11). For 
adjusting the results for differential uptake/availability of the probe in mitochondria, the use of a ratio of the 
phenolic product to probe level was proposed (10, 11). The o-MitoPhB(OH)2 probe (74, 75) was incubated with 
microglial cells (50 μM, 1 h) before collecting the cells. The samples were prepared and analyzed by LC-MS/MS 
using the deuterated analogs d15-MitoPhB(OH)2 and d15-MitoPhOH as the internal standards, as described 
recently (74, 75). 
MitoTracker and MitoSOX 
N27 dopaminergic cells grown on poly-d-lysine-coated glass coverslips in 24-well plates were treated in 2% FBS 
media for 12 h with 0, 10, or 30 μM Mito-apo-C2 or 1 μM rotenone, and then washed twice with PBS. CMXRos 
MitoTracker Red dye (working concentration of 200 nM) was incubated at 37°C for 12 min. ImageJ was used to 
quantify mitochondrial parameters as described previously (8, 14). MitoSOX reagent (working concentration of 
5 μM) was used to detect mitochondrial oxidant(s) production in live N27 cells as per the manufacturer's 
instructions. It should be noted that MitoSOX fluorescence does not allow for identification of the specific type 
of oxidant(s) detected. 
Nitric oxide and cytokine detection 
Microglia were cotreated for 12 h with 1 μg/ml LPS and 0, 10, or 30 μM Mito-apo-C11. Supernatant was used to 
determine extracellular cytokine levels using the Luminex bead-based immunoassay with recombinant 
standards for IL-6, IL-12, TNF-α, and IL-1β. Nitric oxide production was measured as media nitrite levels using 
Griess reagent and sodium nitrite standard curve as previously described (35). 
Animals and treatments 
MitoPark mice were a kind gift of Dr. Nils-Goran Larson at the Max Planck Institute for Biology and Ageing in 
Cologne, Germany. All mice for this study were bred and housed under standard conditions (ad libitum food, a 
12-h light cycle, constant temperature and humidity) at the Iowa State University (ISU) as approved by the 
Institutional Animal Care and Use Committee. MitoPark and age-matched control mice were oral gavaged with 
either 10 mg/kg Mito-apo-C11 dissolved in 10% ethanol in PBS or an equivolume vehicle solution thrice weekly 
from age 13 to 24 weeks. Mice were subjected to behavioral testing, and neurochemical and histological 
measurements were performed at age 24 weeks. 
Behavior 
Open-field and rotarod experiments were performed as previously described (32). Briefly, open-field 
measurements of spontaneous locomotor activity were accomplished using VersaMax (monitor RXYZCM-16, 
analyzer VMAUSB; AccuScan, Columbus, OH) during a 10-min acquisition period following a 2-min 
accustomization. Coordination was assessed by rotarod (AccuScan) performance at 20 rpm for five trials not 
exceeding 20 min. 
HPLC analysis of neurotransmitters 
Striatal lysates were prepared in an antioxidant buffer containing 0.2 M perchloric acid, 0.1% Na2S2O5, 0.05% 
NaEDTA, and isoproterenol as an internal standard as previously described (33). Samples were sonicated for 
2 min, centrifuged for 10 min, and filtered through a 0.2 μm filter before running. Samples were placed into an 
autosampler (WPS-3000TSL; Thermo Scientific) at 4°C and separated isocratically by a reversed-phase C18 
column at 0.6 ml/min (pump, Ultimate 3000 ISO-3100SD). Electrochemical detection (CoulArray 5600A) was 
performed using potentials of 350, 0, −150, and 220 mV (microdialysis cell 5014B, guard cell 5020) to detect 
dopamine, DOPAC, and HVA. Chromatograph integration and analyses were performed using Chromeleon 
(7.1.3) and ESA CoulArray (3.10) software. 
Western blotting 
Western blot lysates from the striatum and SN were prepared in RIPA buffer with protease and phosphatase 
inhibitors (Pierce Biotechnology) and run on a 10–15% sodium dodecyl sulfate/polyacrylamide gel 
electrophoresis (SDS-PAGE) as previously described (33). Following SDS-PAGE electrophoresis, proteins were 
transferred to a nitrocellulose membrane (Bio-Rad). After blocking for 1 h in LiCor blocking buffer or milk, 
primary antibodies including 4-HNE (1:2000), TH (1:1500), iNOS (1:500), IBA1 (1:1200), and β-actin (1:7000) were 
incubated at 4°C overnight. Secondary antibodies (Alexa Fluor 680 and Rockland IR800) were incubated at RT for 
1 h and images were captured via LiCor Odyssey imager. Densitometric analysis was done using ImageJ software. 
IHC and confocal imaging 
Perfusion, sectioning, and IHC were performed as previously described by Ghosh et al. (33). Animals were 
transcardially perfused with PBS and 4% PFA. The next day, brains were cryoprotected with 30% sucrose and 
brain blocks were made in OCT. Cryo-solution containing ethylene glycol and sucrose was used to store 30-μm 
sections until use. Following washing, antigen retrieval was achieved by keeping sections at 80°C for 30 min in 
sodium citrate. Sections were incubated with primary antibodies overnight at 4°C. Appropriate secondary 
antibodies (Alexa Fluor 488 and 555) were incubated with sections for 1.5 h, followed by 7 min with Hoechst 
stain. Dehydrated slides were mounted using DPX. 
Images (20–30 × ) were captured with an inverted microscope attached to a SPOT digital camera. For confocal 
imaging, the ISU Microscopy Facility's Leica DMIRE2 confocal microscope was used to acquire 63 × z-stack 
images, which were converted to maximum projection images using Imaris software. 
DAB immunostaining and cell counting 
For DAB staining, IHC was performed on 30-μm SN sections. A biotinylated secondary antibody followed by 
incubation with an avidin peroxidase solution (Vector labs) was used to yield a brown stain after incubation with 
DAB solution. Stereological counting of TH+ neurons was done on every sixth section at 40 × using Stereo 
Investigator software (MicroBrightField) with an optical fractionator. Images (20 × ) for IBA1+ microglia analysis 
were acquired with Spot software. ImageJ software was used to count microglial cells, adjust threshold, convert 
images to binary, skeletonize, and analyze skeleton (49). 
Electron paramagnetic resonance 
EPR spectra were recorded on a Bruker ELEXSYS E600 spectrometer equipped with a Super-X microwave bridge 
with an integrated microwave counter, an ER4112SHQ resonant cavity operating at 9.38 GHz, and an Oxford 
Instruments ESR900 helium flow cryostat with an ITC503 temperature controller. Spectra were recorded at 12 K 
with 5 mW microwave power and 10 G magnetic field modulation at 100 kHz; this modulation amplitude 
determined the spectral resolution. Scans of 4096 points, an 8000 G field envelope, and a 3-min duration were 
averaged over 60–180 min to provide the final spectrum. A background spectrum collected on frozen water was 
subtracted from experimental spectra. Contributions of each of the paramagnetic centers of the mitochondrial 
proteins to the experimental spectra were estimated by fitting a library of computed spectra corresponding to 
the mitochondrial respiratory chain centers and the [3Fe–4S] cluster of aconitase, using a Levenberg–Marquardt 
algorithm to minimize χ2 (IGOR Pro v. 6.32A; Wavemetrics, Lake Oswego, OR). The contributions of each 
component were constrained to ≥0. Computed spectra of the individual components were calculated, using spin 
Hamiltonian parameters from the literature (23, 26, 36, 40, 50, 58, 72), with XSophe [Bruker Biospin; (38)]. 
Detection of Mito-apo-C11 in brain and blood 
Mice were administered 10 mg/kg Mito-apo-C11 by oral gavage and then sacrificed at 30 min, 3, 6, 12, 24, or 
48 h (n = 3/time point). Blood was collected by cardiac puncture into heparinized tubes for plasma, and various 
brain regions were dissected out and stored at −80°C. Tissue homogenates were then made using antioxidant 
buffer, as described above for neurotransmitter extraction. The standards prepared and used for quantification 
were 0.1, 0.3, 1.0, 10, and 30 μg. Samples were centrifuged and 0.2-μm filtered before analysis on an Agilent 
Technologies 1200 Series HPLC system using a 20 -μl injection volume. Separation was performed with a Kinetex 
C18 column, operated at a flow rate of 1.5 ml/min and a temperature of 40°C, using a gradient elution (solvent 
A = 90% water, 10% acetonitrile, solvent B = 100% acetonitrile) over 10 min. Mito-apo-C11 was quantified by UV 
absorbance (collected at wavelengths of 262 and 292 nm) with an average retention time of 6.35 min. Standards 
were fit to a linear regression and data were analyzed using GraphPad Prism 4.0. 
Statistical analysis 
Data were analyzed by one-way analysis of variance with Bonferroni post-test using Prism 4.0 software. 
Differences with p-values ≤0.05 were considered significant. 
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ALP alkaline phosphatase 
ATRA all-trans retinoic acid 
CBA coumarin boronic acid 
CNS central nervous system 
CRISPR clustered regularly interspaced short palindromic repeats 
DA dopamine 
DMEM Dulbecco's modified Eagle's medium 
l-DOPA l-3,4-dihydroxyphenylalanine 
DOPAC 3,4-dihydroxyphenylacetic acid 
EPR electron paramagnetic resonance 
FBS fetal bovine serum 
FCCP carbonilcyanide p-trifluoromethoxyphenylhydrazone 
HPLC high-performance liquid chromatography 
HPr+ hydropropidine 
HVA homovanillic acid 
IBA1 ionized calcium-binding adapter molecule 1 








MTA mitochondria-targeted antioxidants 
NOX NADPH oxidase 
OCR oxygen consumption rate 
PD Parkinson's disease 
PINK1 PTEN-induced putative kinase 1 
PMA phorbol myristate acetate 
ROS reactive oxygen species 
SN substantia nigra 
TFAM mitochondrial transcription factor A 
TH tyrosine hydroxylase 
TNFα Tumor necrosis factor α 
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